Leerink Swann on DUSA Pharmaceuticals (DUSA): An Unusual Small Cap Opportunity; Steady, Profitable Growth in a Large Market
Tweet
Share
E-mailGet Alerts DUSA Hot Sheet
Price: $57.12 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 9
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 9
Join SI Premium – FREE
Leerink Swann initiates coverage on DUSA Pharmaceuticals (NASDAQ: DUSA) with an Outperform. PT $8.00.
Leerink analyst says, "Positives include: 1) forecasted double-digit sales growth thru '15E as growth of PDT for AK treatment is still in early stages; 2) improved attractiveness to physicians as PDT reimbursement has increased +245% since '04; 3) management's re-focused efforts on the U.S. mkt; 4) potential label improvements driven by 2012 data catalysts designed to simplify and enhance uptake; and 5) scarcity value of small US specialty dermatology company."
"The main investment risks are:1) ability to achieve our revenue forecasts due to competition; 2) visibility on changes to reimbursement ; 3) risk of generic substitution post 2013 when the initial PDT platform patent expires."
For an analyst ratings summary and ratings history on DUSA Pharmaceuticals click here. For more ratings news on DUSA Pharmaceuticals click here.
Shares of DUSA Pharmaceuticals closed at $4.48 yesterday.
Leerink analyst says, "Positives include: 1) forecasted double-digit sales growth thru '15E as growth of PDT for AK treatment is still in early stages; 2) improved attractiveness to physicians as PDT reimbursement has increased +245% since '04; 3) management's re-focused efforts on the U.S. mkt; 4) potential label improvements driven by 2012 data catalysts designed to simplify and enhance uptake; and 5) scarcity value of small US specialty dermatology company."
"The main investment risks are:1) ability to achieve our revenue forecasts due to competition; 2) visibility on changes to reimbursement ; 3) risk of generic substitution post 2013 when the initial PDT platform patent expires."
For an analyst ratings summary and ratings history on DUSA Pharmaceuticals click here. For more ratings news on DUSA Pharmaceuticals click here.
Shares of DUSA Pharmaceuticals closed at $4.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- Jefferies Starts Aehr Test Systems (AEHR) at Buy
- Canaccord Starts Kazia Therapeutics (KZIA) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
